The Experts below are selected from a list of 203724 Experts worldwide ranked by ideXlab platform
Josef Smolen - One of the best experts on this subject based on the ideXlab platform.
-
Autoantibodies in rheumatoid arthritis and their clinical significance
Arthritis Research & Therapy, 2002Co-Authors: Günter Steiner, Josef SmolenAbstract:Autoantibodies are proven useful diagnostic tools for a variety of rheumatic and non-rheumatic autoimmune disorders. However, a highly specific marker autoantibody for rheumatoid arthritis (RA) has not yet been determined. The presence of rheumatoid factors is currently used as a marker for RA. However, rheumatoid factors have modest specificity (~70%) for the disease. In recent years, several newly characterized Autoantibodies have become promising candidates as diagnostic indicators for RA. Antikeratin, anticitrullinated peptides, anti-RA33, anti-Sa, and anti-p68 Autoantibodies have been shown to have >90% specificity for RA. These Autoantibodies are reviewed and the potential role of the Autoantibodies in the pathogenesis of RA is briefly discussed.
Bart Keymeulen - One of the best experts on this subject based on the ideXlab platform.
-
predictive power of screening for antibodies against insulinoma associated protein 2 beta ia 2β and zinc transporter 8 to select first degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease implic
Diabetologia, 2010Co-Authors: J De Grijse, Isabel Vermeulen, M. Asanghanwa, B Nouthe, N Albrecher, Patrick Goubert, S Van Der Meeren, K Decochez, I Weets, Bart KeymeulenAbstract:Aims/hypothesis We investigated whether screening for insulinoma-associated protein (IA-2) beta (IA-2β) Autoantibodies (IA-2βA) and zinc transporter-8 (ZnT8) Autoantibodies (ZnT8A) improves identification of first-degree relatives of type 1 diabetic patients with a high 5-year disease risk, which to date has been based on assays for insulin Autoantibodies (IAA), GAD Autoantibodies (GADA) and IA-2 Autoantibodies (IA-2A).
-
Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: imp
Diabetologia, 2010Co-Authors: J De Grijse, Isabel Vermeulen, M. Asanghanwa, B Nouthe, N Albrecher, Patrick Goubert, K Decochez, I Weets, S. Meeren, Bart KeymeulenAbstract:Aims/hypothesis We investigated whether screening for insulinoma-associated protein (IA-2) beta (IA-2β) Autoantibodies (IA-2βA) and zinc transporter-8 (ZnT8) Autoantibodies (ZnT8A) improves identification of first-degree relatives of type 1 diabetic patients with a high 5-year disease risk, which to date has been based on assays for insulin Autoantibodies (IAA), GAD Autoantibodies (GADA) and IA-2 Autoantibodies (IA-2A). Methods IA-2βA and ZnT8A (using a ZnT8 carboxy-terminal hybrid construct, CW-CR, carrying 325Arg and 325Trp) were determined by radiobinding assay in 409 IAA^+, GADA^+ and/or IA-2A^+ siblings or offspring (
Günter Steiner - One of the best experts on this subject based on the ideXlab platform.
-
Autoantibodies in rheumatoid arthritis and their clinical significance
Arthritis Research & Therapy, 2002Co-Authors: Günter Steiner, Josef SmolenAbstract:Autoantibodies are proven useful diagnostic tools for a variety of rheumatic and non-rheumatic autoimmune disorders. However, a highly specific marker autoantibody for rheumatoid arthritis (RA) has not yet been determined. The presence of rheumatoid factors is currently used as a marker for RA. However, rheumatoid factors have modest specificity (~70%) for the disease. In recent years, several newly characterized Autoantibodies have become promising candidates as diagnostic indicators for RA. Antikeratin, anticitrullinated peptides, anti-RA33, anti-Sa, and anti-p68 Autoantibodies have been shown to have >90% specificity for RA. These Autoantibodies are reviewed and the potential role of the Autoantibodies in the pathogenesis of RA is briefly discussed.
Socrates J. Tzartos - One of the best experts on this subject based on the ideXlab platform.
-
Extracellular domains of the β, γ and ε subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic Autoantibodies: A combination of immunoadsorbents results in increased efficiency
Journal of Neuroimmunology, 2007Co-Authors: Kalliopi Kostelidou, Nikolaos Trakas, Socrates J. TzartosAbstract:Abstract Myasthenia gravis (MG) is usually caused by Autoantibodies against the human muscle acetylcholine receptor (AChR). Plasmapheresis offers a therapeutic option, but, as well as removing the pathogenic anti-AChR Autoantibodies, it non-specifically removes indispensable immunoglobulins. An attractive alternative to plasmapheresis would be the extracorporeal specific removal of the Autoantibodies using AChR-based immunoadsorbents. Previously, we used the N-terminal extracellular domain (ECD) of the AChR α subunit to immunoadsorb anti-α subunit Autoantibodies from MG sera. In this study, we immobilised the β -, γ- and e-AChR ECDs on Sepharose and tested them as immunoadsorbents on 50 MG sera. A given ECD removed a different percentage of Autoantibodies from different sera and different ECDs removed different percentages from the same serum; on average, the β-, γ- and e-ECDs removed 22%, 20% and 15.5% of the Autoantibodies, respectively. Immunoadsorption was completed in 3 min, 1 μg of ECD removed ∼ 2 pmol of Autoantibodies, and the immunoadsorbent could be recycled ∼ 4 times. The combined use of two (α + γ) or four (α + β + γ + e) ECDs in a single immunoadsorbent resulted in much higher (often additive) immunoadsorption. These results show that MG sera have Autoantibodies against several AChR subunits, and suggest that the combined use of all AChR ECDs could provide the basis for a novel, antigen-specific therapy for MG.
-
Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic Autoantibodies: a combination of immunoadsorbents results in increased efficiency.
Journal of neuroimmunology, 2007Co-Authors: Kalliopi Kostelidou, Nikolaos Trakas, Socrates J. TzartosAbstract:Myasthenia gravis (MG) is usually caused by Autoantibodies against the human muscle acetylcholine receptor (AChR). Plasmapheresis offers a therapeutic option, but, as well as removing the pathogenic anti-AChR Autoantibodies, it non-specifically removes indispensable immunoglobulins. An attractive alternative to plasmapheresis would be the extracorporeal specific removal of the Autoantibodies using AChR-based immunoadsorbents. Previously, we used the N-terminal extracellular domain (ECD) of the AChR alpha subunit to immunoadsorb anti-alpha subunit Autoantibodies from MG sera. In this study, we immobilised the beta -, gamma- and epsilon-AChR ECDs on Sepharose and tested them as immunoadsorbents on 50 MG sera. A given ECD removed a different percentage of Autoantibodies from different sera and different ECDs removed different percentages from the same serum; on average, the beta-, gamma- and epsilon-ECDs removed 22%, 20% and 15.5% of the Autoantibodies, respectively. Immunoadsorption was completed in 3 min, 1 mug of ECD removed approximately 2 pmol of Autoantibodies, and the immunoadsorbent could be recycled approximately 4 times. The combined use of two (alpha+gamma) or four (alpha+beta+gamma+epsilon) ECDs in a single immunoadsorbent resulted in much higher (often additive) immunoadsorption. These results show that MG sera have Autoantibodies against several AChR subunits, and suggest that the combined use of all AChR ECDs could provide the basis for a novel, antigen-specific therapy for MG.
B R Smith - One of the best experts on this subject based on the ideXlab platform.
-
Thyroid Autoantibodies.
Scandinavian journal of clinical and laboratory investigation. Supplementum, 2001Co-Authors: B R SmithAbstract:The characteristics of thyroid Autoantibodies are reviewed and new assays for the Autoantibodies described, in particular point of care (POC) tests for thyroid peroxidase (TPO) Autoantibodies and for thyroglobulin (Tg) Autoantibodies. These POC tests depend on the ability of the Autoantibodies to inhibit gold labelled human monoclonal antibodies binding to TPO or to Tg. The POC tests show similar sensitivity and specificity to conventional ELISA for the Autoantibodies. A new ELISA to measure Autoantibodies to the TSH receptor (TRAb) is described, is based on TSH receptor coated onto plate wells by way of a monoclonal antibody. Comparison of porcine and human TSH receptors indicates that there is no advantage in using human TSHR in assay systems based on competition between TRAb and bovine or porcine TSH for immobilised TSHR. In terms of the origins of Graves' disease, it is speculated that this most common overt autoimmune disease in man might have occurred first when Homo sapiens sapiens migrated rapidly out of Africa about 100,000 years ago.
